Connor, Clark & Lunn Investment Management (CC&L)
AUPH icon

Connor, Clark & Lunn Investment Management (CC&L)’s Aurinia Pharmaceuticals AUPH Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.86M Buy
395,405
+11,782
+3% +$172K 0.01% 639
2025
Q4 		$6.12M Sell
383,623
-157,565
-29% -$2.23M 0.02% 588
2025
Q3 		$5.98M Sell
541,188
-109,003
-17% -$1.19M 0.02% 531
2025
Q2 		$5.51M Sell
650,191
-96,038
-13% -$770K 0.02% 547
2025
Q1 		$6M Buy
746,229
+189,775
+34% +$1.54M 0.03% 459
2024
Q4 		$5M Buy
556,454
+102,195
+22% +$834K 0.02% 481
2024
Q3 		$3.33M Buy
+454,259
New +$2.82M 0.02% 542
2021
Q3 		– Sell
-367,000
Closed -$4.76M – 1031
2021
Q2 		$4.76M Sell
367,000
-68,912
-16% -$878K 0.02% 368
2021
Q1 		$5.67M Sell
435,912
-1,564,060
-78% -$22.7M 0.03% 328
2020
Q4 		$27.6M Buy
1,999,972
+379,280
+23% +$5.52M 0.16% 118
2020
Q3 		$23.9M Buy
1,620,692
+166,792
+11% +$2.42M 0.16% 121
2020
Q2 		$23.6M Buy
1,453,900
+376,330
+35% +$6.03M 0.17% 108
2020
Q1 		$15.7M Buy
+1,077,570
New +$19M 0.14% 123

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s AUPH Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Aurinia Pharmaceuticals (AUPH) stake by 3.1% in Q1 2026, buying an estimated $172K and bringing the position to 395,405 shares worth $5.86M. The position accounts for 0.01% of the portfolio, ranked #639.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in AUPH in Q1 2020 and has held it in 13 quarters since. The position peaked at $27.6M in Q4 2020. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 395,405 shares of Aurinia Pharmaceuticals worth $5.86M as of Q1 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) bought 11,782 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $172K.
  • Aurinia Pharmaceuticals made up 0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #639 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Aurinia Pharmaceuticals in Q1 2020 and has held it in 13 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Aurinia Pharmaceuticals position peaked at $27.6M in Q4 2020.
  • 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.